"Laurence brings a wealth of urological expertise to miR as a clinical trialist, urologic oncologist and collaborative research partner during an exciting time in our company's growth," said Sam Salman, Chief Executive Officer of miR Scientific. "His ability to synthesize his decades of experience as an industry leader will help guide miR Scientific's clinical development efforts and regulatory strategies. With the addition of Laurence to our team, we are well positioned to maximize the high priority opportunities available to us through our urogenital cancer platform, which includes advanced, non-invasive liquid biopsy screening tests to diagnose bladder and prostate cancers. His active participation in this year's Friends of Israel Urological Symposium highlights the esteemed position he holds amongst world-renowned colleagues."
Dr. Klotz currently serves as the Chairman of the World Urologic Oncology Federation and Member of the Institute of Medical Science and Graduate Faculty at the University of Toronto since July 2005. He also serves as the Chairman of the Canadian Urology Research Consortium of Toronto since July 2004. Since May 2000, he serves as Professor of Surgery at the University of Toronto and has been an active staff and is the past chief at the Division of Urology at Sunnybrook Health Sciences Centre in Toronto since 1985. He holds numerous distinctions and research awards including the Richard Williams Award from the American Urological Association, which is presented to individuals for their outstanding and impactful research in the field of prostate cancer, the Dean's lifetime achievement award from the University of Toronto, and the Order of Canada, Canada's highest civilian honor. Dr. Klotz received a BSc and MD from the University of Toronto.
"miR Scientific's platform has the prospect to be truly transformative," said Dr. Klotz. "It is rare to be presented with an opportunity to develop breakthrough technologies with such significant potential that have promising data in two urologic cancers. The prospect that miR Scientific can disrupt legacy diagnostic methodologies such as prostate-specific antigen (PSA) screening through the Company's Sentinel™ Prostate Diagnostic Test (miR-PDx) for prostate cancer is notable. I look forward to this exciting challenge and the potential to have a meaningful impact on patients and their families.""We look forward to working with Dr. Klotz, who is based in Toronto, to expand our clinical development in strategic hubs within North America," commented Robert Tenniswood, President of miR Scientific Canada, Inc. "His contributions can more rapidly expand our pipeline dedicated to advancing miR's urogenital cancer platform."
- Sponsored Fourth Friends of Israel Urological Symposium-
Further Related Content:
A Presentstion by Laurence Klotz, MD from the 2018 Fourth Friends of Israel Urological Symposium - Intermediate Risk Prostate Cancer Case with a 1 cm PZ Lesion on MRI - What is the Preferred Treatment?